

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	REILLY ET AL.	Examiner:	C. CROWDER
Serial No.:	10/697,995	Group Art Unit:	1644
Filed:	OCTOBER 30, 2003	Docket No.:	11669.195USU1
Confirmation No.:	7395	Customer No.:	23552
Title:	METHODS AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(37 C.F.R. § 1.97(c))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Please charge Deposit Account No. 13-2725 for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: October 27, 2006

Katherine M. Kowalchuk
Katherine M. Kowalchuk
Reg. No. 36,848



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number 11669.195USU1	Application Number 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1644

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 05/027966 A2	03/31/05	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Eccles, "Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?", <u>Breast Cancer Res.</u> , 3:86-90 (2001)
	Reff et al., "A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications", <u>Oncology Hematology</u> , 40:25-35 (2001)
	Tutt et al., "Monoclonal Antibody Therapy of B Cell Lymphoma: Signalling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors", <u>The Journal of Immunology</u> , 161:3176-3185 (1998)
	Yoshida et al., "Ganglioside G ₉₂ in Small Cell Lung Cancer Cell Lines: Enhancement of Cell Proliferation and Mediation of Apoptosis", <u>Cancer Research</u> , 61 4244-4252 (2001)

23552

PATENT TRADE MARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	